Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Figure 7




Figure 8





Figure 9






Figure 11

on BN-472 mammary tumor load in Brown Norway rats Effects of epirubicin, WX-UK1 and epirubicin + WX-UK




Figure 12

Effects of epirubicin, WX-UK1 and epirubicin + WX-UK1 on BN-472 mammary fumor weight in Brown Norway rats




Figure 13

Effects of epirubicin, WX-UK1 and epirubicin + WX-UK1 administrations on axillary lymph-node weight




Figure 14




Figure 15






Figure 16

Effects of paclitaxel, WX-UK1, and paclitaxel + WX-UK1 administrations on axillary lymph-node weight




Figure 17

Effects of paclitaxel, WX-UK1, paclitaxel + WX-UK1 administrations on intraperitoneal lymph-node weight




Figure 18

administrations on the number of macroscopic lung foci Effects of paclitaxel, WX-UK1 and paclitaxel + WX-UK1




Figure 19

Effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 on BN-472 mammary tumor growth in Brown Norway rats




Figure 20

Effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 on BN-472 mammary fumor burden in Brown Norway rats





Figure 21

Effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 on BN-472 mammary tumor burden in Brown Norway rats



treatment group

tumor weight (g)

Figure 22

Anti metastatic effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 in Brown Norway rats bearing BN-472 mammary tumors





Figure 23

Anti metastatic effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 in Brown Norway rats bearing BN-472 mammary tumors



I.P. lymph-node weight (mg)

Figure 24

Anti metastatic effects of 5-FU, WX-UK1, and 5-FU + WX-UK1 in Brown Norway rats bearing BN-472 mammary tumors

